Aldeyra Therapeutics Enters Material Agreement, Incurs Financial Obligation
Ticker: ALDX · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1341235
| Field | Detail |
|---|---|
| Company | Aldeyra Therapeutics, INC. (ALDX) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $300,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Aldeyra just signed a big deal and owes money, filing shows.
AI Summary
Aldeyra Therapeutics, Inc. entered into a material definitive agreement on September 30, 2024, which also created a direct financial obligation for the registrant. The filing was made on October 2, 2024, and pertains to the company's financial reporting and obligations.
Why It Matters
This filing indicates a significant new financial commitment or agreement for Aldeyra Therapeutics, which could impact its financial health and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and incurring financial obligations can introduce financial risks and operational changes that warrant investor attention.
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- September 30, 2024 (date) — Date of earliest event reported
- October 2, 2024 (date) — Date of Report
FAQ
What is the nature of the material definitive agreement Aldeyra Therapeutics entered into?
The filing states that Aldeyra Therapeutics, Inc. entered into a material definitive agreement on September 30, 2024, but the specific details of the agreement are not provided in this excerpt.
What type of financial obligation did Aldeyra Therapeutics incur?
The filing indicates the creation of a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant' on September 30, 2024, but the exact nature and amount are not detailed here.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on October 2, 2024.
What is Aldeyra Therapeutics' fiscal year end?
Aldeyra Therapeutics' fiscal year ends on December 31.
What is Aldeyra Therapeutics' business address?
Aldeyra Therapeutics' business address is 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
Filing Stats: 837 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-10-02 16:10:54
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
- $300,000 — n, a supplemental end of term charge of $300,000 shall be due on the earlier of (A) the
Filing Documents
- d875044d8k.htm (8-K) — 27KB
- d875044dex102.htm (EX-10.2) — 35KB
- 0001193125-24-231158.txt ( ) — 191KB
- aldx-20240930.xsd (EX-101.SCH) — 3KB
- aldx-20240930_lab.xml (EX-101.LAB) — 18KB
- aldx-20240930_pre.xml (EX-101.PRE) — 11KB
- d875044d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Loan and Security Agreement, dated as of March 25, 2019, by and among the Registrant, certain subsidiaries of the Registrant from time to time party thereto, the several banks and other financial institutions or entities from time to time parties thereto and Hercules Capital, Inc. (filed as Exhibit 10.1 to the Registrant's Current Report on Form 8-K (as filed on March 26, 2019, and incorporated herein by reference)) 10.2 Fourth Amendment to Loan and Security Agreement, dated September 30, 2024, by and among Aldeyra Therapeutics, Inc., Helio Vision, LLC, the several banks and other financial institutions or entities from time to time parties thereto and Hercules Capital, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady M.D., Ph.D. Title: Chief Executive Officer Dated October 2, 2024